{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:10:23Z","timestamp":1785813023466,"version":"3.56.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Corticosteroids are extensively used in ophthalmology, particularly for treating various inflammatory conditions. Despite their effectiveness, prolonged or high-dose corticosteroid use is associated with significant adverse drug reactions (ADRs), such as increased intraocular pressure, cataract formation, and secondary infections. However, there is currently no systematic study comparing the side effects of ophthalmic corticosteroids. This study aims to investigate the safety profiles of ophthalmic corticosteroids through pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective analysis of ADR reports related to commonly used ophthalmic corticosteroids from the FAERS database, covering the period from Q1 2004 to Q4 2023. Clinical features such as gender, age, administration route, and dosage form were also analyzed. Signal detection methods, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and the Multi-Item Gamma Poisson Shrinker (MGPS), were used to identify potential safety signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 9,854 ADRs related to ophthalmic corticosteroids were retrieved, with the most frequently reported drugs being Ozurdex (1,784 cases), Lotemax (3,239 cases), and Durezol (2,789 cases). Women accounted for a higher proportion of ADRs across most corticosteroids. ADR induction time analysis results showed that ADRs tend to occur in the early stages of drug use. The most common ophthalmic ADRs identified included eye inflammation, cataract, visual impairment, uveitis, eye pain, blurred vision, and retinal detachment. Additionally, Maxidex has been linked to endocrine disorders, while Ozurdex, Iluvien, and Triesence exhibited significant signals for product issues, likely related to their intraocular injection procedures. Notably, cataract was the most common PT among these drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study reveals significant safety concerns related to using ophthalmic corticosteroids, particularly regarding adverse reactions that can impact visual function. These findings highlight the need for careful monitoring and individualized treatment plans to minimize the risk of ADRs in patients receiving corticosteroid therapy. Future studies combining FAERS data with large-scale clinical research are needed to explore these safety concerns further.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1502047","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T04:41:48Z","timestamp":1733892108000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study"],"prefix":"10.3389","volume":"15","author":[{"given":"Chengzhi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xusheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.ophtha.2018.04.035","article-title":"Adrenal suppression in infants treated with topical ocular glucocortic oids","volume":"125","author":"Bangsgaard","year":"2018","journal-title":"Ophthalmology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/sj.bjp.0706736","article-title":"How corticosteroids control inflammation: quintiles prize lecture 2005","volume":"148","author":"Barnes","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1177\/11206721241237069","article-title":"Management of treatment-na\u00efve diabetic macular edema patients: review of real-world clinical data","volume":"34","author":"Boscia","year":"2024","journal-title":"Eur. J. Ophthalmol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jphs.2018.11.001","article-title":"Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies","volume":"138","author":"Bucolo","year":"2018","journal-title":"J. Pharmacol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00592-018-1151-x","article-title":"Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema","volume":"55","author":"Busch","year":"2018","journal-title":"Acta Diabetol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jaad.2016.02.1241","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients","volume":"76","author":"Caplan","year":"2017","journal-title":"J. Am. Acad. Dermatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/00055735-200012000-00016","article-title":"Ocular complications of topical, peri-ocular, and systemic corticosteroids","volume":"11","author":"Carnahan","year":"2000","journal-title":"Curr. Opin. Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0091-6749(75)90010-x","article-title":"How corticosteroids work","volume":"55","author":"Claman","year":"1975","journal-title":"J. Allergy Clin. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/09273948.2017.1341988","article-title":"The use of topical corticosteroids for treatment of dry eye syndrome","volume":"27","author":"Cutolo","year":"2019","journal-title":"Ocular Immunol. Inflamm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/children11080951","article-title":"Systemic adverse events associated with locally administered corticosteroids","volume":"11","author":"De Vleeschhauwer","year":"2024","journal-title":"Child. (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.joco.2019.05.002","article-title":"Ocular adverse events with immune checkpoint inhibitors","volume":"31","author":"Fang","year":"2019","journal-title":"J. Curr. Ophthalmol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/pds.4672","article-title":"Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA","volume":"27","author":"Fukazawa","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/ceo.13702","article-title":"Local delivery of corticosteroids in clinical ophthalmology: a review","volume":"48","author":"Fung","year":"2020","journal-title":"Clin. Exp. Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s13346-020-00843-z","article-title":"Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives","volume":"11","author":"Gaballa","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"Cd013101","DOI":"10.1002\/14651858.CD013101.pub2","article-title":"Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass","volume":"10","author":"Gibbison","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/healthcare11101479","article-title":"Severe gastrointestinal toxicity following the use of gilteritinib: a case series and analysis of postmarketing surveillance data","volume":"11","author":"Gozzo","year":"2023","journal-title":"Healthc. (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"748766","DOI":"10.3389\/fphar.2021.748766","article-title":"Off-label use of venetoclax in patients with acute myeloid leukemia: single center experience and data from pharmacovigilance database","volume":"12","author":"Gozzo","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","article-title":"Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS)","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann. rheumatic Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/jop.2006.0067","article-title":"The etiology of steroid cataract","volume":"23","author":"James","year":"2007","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1444-0938.2002.tb03011.x","article-title":"What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts","volume":"85","author":"Jobling","year":"2002","journal-title":"Clin. Exp. Optom."},{"key":"B23","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/NOR.0000000000000595","article-title":"Corticosteroids","volume":"38","author":"Kapugi","year":"2019","journal-title":"Orthop. Nurs."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1517\/14656566.2012.690736","article-title":"Intraocular corticosteroids for posterior segment disease: 2012 update","volume":"13","author":"Kiernan","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2288-14-17","article-title":"Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases","volume":"14","author":"Leroy","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1017889","DOI":"10.3389\/fphar.2022.1017889","article-title":"Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","article-title":"Locally administered ocular corticosteroids: benefits and risks","volume":"25","author":"Mcghee","year":"2002","journal-title":"Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","article-title":"Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles?","volume":"37","author":"Michel","year":"2017","journal-title":"Clin. drug Investig."},{"key":"B29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","article-title":"Gender differences in autoimmune disease","volume":"35","author":"Ngo","year":"2014","journal-title":"Front. Neuroendocrinol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.3390\/molecules26154673","article-title":"Lipid nanoparticles traverse non-corneal path to reach the posterior eye segment: in vivo evidence","volume":"26","author":"Puglia","year":"2021","journal-title":"Molecules"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archopht.1996.01100140208016","article-title":"Corticosteroid therapy of eye disease: fifty years later","volume":"114","author":"Raizman","year":"1996","journal-title":"Archives Ophthalmol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.survophthal.2020.01.002","article-title":"Steroid-induced glaucoma: epidemiology, pathophysiology, and clinical management","volume":"65","author":"Roberti","year":"2020","journal-title":"Surv. Ophthalmol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3390\/pharmaceutics15051370","article-title":"Fluoxetine protects retinal ischemic damage in mice","volume":"15","author":"Romano","year":"2023","journal-title":"Pharmaceutics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/eye.2012.12","article-title":"Do topical ophthalmic corticosteroids suppress the hypothalmic-pituitary-adrenal axis in post-penetrating keratoplasty patients?","volume":"26","author":"Sandhu","year":"2012","journal-title":"Eye"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1136\/bjo.87.10.1247","article-title":"A population based case-control study of cataract and inhaled corticosteroids","volume":"87","author":"Smeeth","year":"2003","journal-title":"Br. J. Ophthalmol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"444","DOI":"10.5530\/jyp.2018.10.97","article-title":"A comparative study of data mining algorithms used for signal detection in FDA AERS database","volume":"10","author":"Subeesh","year":"2018","journal-title":"J. Young Pharm."},{"key":"B38","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.4103\/0976-500X.120947","article-title":"Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases","volume":"4","author":"Ventrice","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1504\/ijbdm.2020.10034546","article-title":"A systematic approach to 'cleaning' of drug name records data in the FAERS database: a case report","volume":"1","author":"Veronin","year":"2020","journal-title":"Int. J. Big Data Manag."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/jcph.2052","article-title":"Pegylated asparaginase-induced liver injury: a case-based review and data from pharmacovigilance","volume":"62","author":"Vetro","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ophtha.2008.12.001","article-title":"Use of inhaled and oral corticosteroids and the long-term risk of cataract","volume":"116","author":"Wang","year":"2009","journal-title":"Ophthalmology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/bcp.15494","article-title":"Ocular disorders associated with PCSK9 inhibitors: a pharmacovigilance disproportionality analysis","volume":"89","author":"Zhao","year":"2023","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1502047\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T04:41:54Z","timestamp":1733892114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1502047\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":42,"alternative-id":["10.3389\/fphar.2024.1502047"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1502047","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"article-number":"1502047"}}